Elevated CHI3L1 levels in the bloodstream are linked to more aggressive tumor behavior, reduced effectiveness of standard therapies, and shorter survival times, offering a clearer yet concerning view of glioblastoma progression [64, 99, 100]. This evidence concerns the gene CHI3L1 and glioblastoma.